← Back to Search

Motor Rehabilitation for Stroke

N/A
Waitlist Available
Led By Yousef Hannawi, MD
Research Sponsored by Ohio State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Kidney disease as evidenced by eGFR<60
Anemia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up participants will be followed for 4-6 weeks. change in motor function at mid-treatment (after 1 week of ci therapy), post-treatment (after 2 weeks of therapy), and at 2-week follow-up will be measured.
Awards & highlights
No Placebo-Only Group

Summary

This trial will help researchers understand how constraint-induced movement therapy (CI therapy) helps the brain "rewire" itself after stroke, in hopes of improving rehabilitation methods.

Who is the study for?
This trial is for adults over 18 who had a stroke at least 6 months ago, resulting in mild to moderate hemiparesis but can still understand and participate in therapy. It's not for those with severe medical conditions, recent botulinum toxin injections, intensive post-stroke rehab, kidney issues, metallic/electronic implants incompatible with MRI, or claustrophobia.
What is being tested?
The study tests Constraint-induced movement therapy (CI therapy) which helps the brain 'rewire' after chronic stroke. Using advanced MRI techniques to observe changes in grey matter and blood flow will infer cellular processes behind brain reorganization during CI therapy.
What are the potential side effects?
Since this trial involves non-invasive MRI scans and physical rehabilitation exercises rather than drugs or invasive procedures, side effects are minimal but may include discomfort from remaining still during scans or fatigue from the exercises.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My kidney function is reduced with an eGFR below 60.
Select...
I have anemia.
Select...
I do not have severe health issues like dementia or uncontrollable pain.
Select...
I have received a botulinum toxin injection in the last 3 months.
Select...
I have sickle cell disease.
Select...
I have had a kidney transplant.
Select...
I have a history of kidney disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~participants will be followed for 4-6 weeks. change in brain structure at mid-treatment (after 1 week of ci therapy), post-treatment (after 2 weeks of therapy), and at 2-week follow-up will be measured.
This trial's timeline: 3 weeks for screening, Varies for treatment, and participants will be followed for 4-6 weeks. change in brain structure at mid-treatment (after 1 week of ci therapy), post-treatment (after 2 weeks of therapy), and at 2-week follow-up will be measured. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Brain structure
Secondary study objectives
Motor function

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Immediate CI therapyExperimental Treatment1 Intervention
Group II: Delayed CI therapyActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CI therapy
2010
N/A
~30

Find a Location

Who is running the clinical trial?

Ohio State UniversityLead Sponsor
866 Previous Clinical Trials
655,093 Total Patients Enrolled
14 Trials studying Stroke
6,415 Patients Enrolled for Stroke
Yousef Hannawi, MDPrincipal InvestigatorOhio State University

Media Library

CI therapy Clinical Trial Eligibility Overview. Trial Name: NCT01725919 — N/A
Stroke Research Study Groups: Immediate CI therapy, Delayed CI therapy
Stroke Clinical Trial 2023: CI therapy Highlights & Side Effects. Trial Name: NCT01725919 — N/A
CI therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT01725919 — N/A
~2 spots leftby Nov 2025